{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:06:39Z","timestamp":1792789599475,"version":"4.5.0"},"reference-count":166,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T00:00:00Z","timestamp":1739836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T00:00:00Z","timestamp":1739836800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1038\/s41571-025-00992-5","type":"journal-article","created":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T09:50:00Z","timestamp":1739872200000},"page":"241-261","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["Outcome correlates of approved CD19-targeted CAR T cells for large B cell lymphoma"],"prefix":"10.1038","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-3744-0466","authenticated-orcid":false,"given":"Tamara J.","family":"Bock","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0171-6206","authenticated-orcid":false,"given":"Chanukya K.","family":"Colonne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4432-2215","authenticated-orcid":false,"given":"Salvatore","family":"Fiorenza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4722-4461","authenticated-orcid":false,"given":"Cameron J.","family":"Turtle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,18]]},"reference":[{"key":"992_CR1","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu, S. S. et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N. Engl. J. Med. 377, 2531\u20132544 (2017).","journal-title":"N. Engl. J. Med."},{"key":"992_CR2","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster, S. J. et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N. Engl. J. Med. 380, 45\u201356 (2019).","journal-title":"N. Engl. J. Med."},{"key":"992_CR3","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","volume":"396","author":"JS Abramson","year":"2020","unstructured":"Abramson, J. S. et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet 396, 839\u2013852 (2020).","journal-title":"Lancet"},{"key":"992_CR4","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","volume":"386","author":"FL Locke","year":"2022","unstructured":"Locke, F. L. et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N. Engl. J. Med. 386, 640\u2013654 (2022).","journal-title":"N. Engl. J. Med."},{"key":"992_CR5","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","volume":"399","author":"M Kamdar","year":"2022","unstructured":"Kamdar, M. et al. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet 399, 2294\u20132308 (2022).","journal-title":"Lancet"},{"key":"992_CR6","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa2116596","volume":"386","author":"MR Bishop","year":"2022","unstructured":"Bishop, M. R. et al. Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma. N. Engl. J. Med. 386, 629\u2013639 (2022).","journal-title":"N. Engl. J. Med."},{"key":"992_CR7","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/S1470-2045(22)00339-4","volume":"23","author":"A Sehgal","year":"2022","unstructured":"Sehgal, A. et al. Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study. Lancet. Oncol. 23, 1066\u20131077 (2022).","journal-title":"Lancet. Oncol."},{"key":"992_CR8","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/s41591-022-01731-4","volume":"28","author":"SS Neelapu","year":"2022","unstructured":"Neelapu, S. S. et al. Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial. Nat. Med. 28, 735\u2013742 (2022).","journal-title":"Nat. Med."},{"issue":"Suppl. 1","key":"992_CR9","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1182\/blood-2019-130983","volume":"134","author":"S Jaglowski","year":"2019","unstructured":"Jaglowski, S. et al. Tisagenlecleucel chimeric antigen receptor (CAR) T-cell therapy for adults with diffuse large B-cell lymphoma (DLBCL): real world experience from the Center for International Blood & Marrow Transplant Research (CIBMTR) Cellular Therapy (CT) Registry [abstract]. Blood 134 (Suppl. 1), 766 (2019).","journal-title":"Blood"},{"issue":"Suppl. 1","key":"992_CR10","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1182\/blood-2023-180242","volume":"142","author":"JL Crombie","year":"2023","unstructured":"Crombie, J. L. et al. Multicenter, real-world study in patients with R\/R large B-cell lymphoma (LBCL) who received lisocabtagene maraleucel (liso-cel) in the United States (US) [abstract]. Blood 142 (Suppl. 1), 104 (2023).","journal-title":"Blood"},{"issue":"Suppl. 1","key":"992_CR11","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1182\/blood-2019-124750","volume":"134","author":"MC Pasquini","year":"2019","unstructured":"Pasquini, M. C. et al. Post-marketing use outcomes of an anti-CD19 chimeric antigen receptor (CAR) T cell therapy, axicabtagene ciloleucel (Axi-Cel), for the treatment of large B cell lymphoma (LBCL) in the United States (US) [abstract]. Blood 134 (Suppl. 1), 764 (2019).","journal-title":"Blood"},{"issue":"Suppl. 1","key":"992_CR12","doi-asserted-by":"crossref","first-page":"7500","DOI":"10.1182\/blood-2022-168399","volume":"140","author":"N Perera","year":"2022","unstructured":"Perera, N. et al. Real-world outcomes with CD19 CAR T-cell therapy for B-cell malignancies in regional\/rural australia: results from the Queensland CAR T-cell program [abstract]. Blood 140 (Suppl. 1), 7500\u20137501 (2022).","journal-title":"Blood"},{"issue":"Suppl. 1","key":"992_CR13","doi-asserted-by":"crossref","first-page":"6936","DOI":"10.1182\/blood-2023-182580","volume":"142","author":"R Alasbali","year":"2023","unstructured":"Alasbali, R. et al. The outcome of tisagenlecleucel (Tisa-Cel) vs axicabtagene ciloleucel (Axi-Cel) CD-19 CAR-T cell therapy in relapsed\/refractory NHL, real world data, single institution experience [abstract]. Blood 142 (Suppl. 1), 6936 (2023).","journal-title":"Blood"},{"key":"992_CR14","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1007\/s10147-020-01699-6","volume":"25","author":"H Goto","year":"2020","unstructured":"Goto, H. et al. Efficacy and safety of tisagenlecleucel in Japanese adult patients with relapsed\/refractory diffuse large B-cell lymphoma. Int. J. Clin. Oncol. 25, 1736\u20131743 (2020).","journal-title":"Int. J. Clin. Oncol."},{"key":"992_CR15","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1200\/JCO.19.02103","volume":"38","author":"CA Jacobson","year":"2020","unstructured":"Jacobson, C. A. et al. Axicabtagene ciloleucel in the non-trial setting: outcomes and correlates of response, resistance, and toxicity. J. Clin. Oncol. 38, 3095\u20133106 (2020).","journal-title":"J. Clin. Oncol."},{"key":"992_CR16","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.19.02104","volume":"38","author":"LJ Nastoupil","year":"2020","unstructured":"Nastoupil, L. J. et al. Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US Lymphoma CAR T consortium. J. Clin. Oncol. 38, 3119\u20133128 (2020).","journal-title":"J. Clin. Oncol."},{"issue":"Suppl. 1","key":"992_CR17","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1182\/blood-2019-127490","volume":"134","author":"PA Riedell","year":"2019","unstructured":"Riedell, P. A. et al. A multicenter retrospective analysis of clinical outcomes, toxicities, and patterns of use in institutions utilizing commercial axicabtagene ciloleucel and tisagenlecleucel for relapsed\/refractory aggressive B-cell lymphomas [abstract]. Blood 134 (Suppl. 1), 1599 (2019).","journal-title":"Blood"},{"key":"992_CR18","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1002\/cam4.3881","volume":"10","author":"G Iacoboni","year":"2021","unstructured":"Iacoboni, G. et al. Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphoma. Cancer Med. 10, 3214\u20133223 (2021).","journal-title":"Cancer Med."},{"key":"992_CR19","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/bjh.19521","volume":"205","author":"T Othman","year":"2024","unstructured":"Othman, T. et al. Real-world experience of axicabtagene ciloleucel, a CD19-directed CAR T-cell therapy, in the second-line treatment of early relapsed or primary refractory large B-cell lymphoma. Br. J. Haematol. 205, 368\u2013372 (2024).","journal-title":"Br. J. Haematol."},{"key":"992_CR20","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1080\/10428194.2022.2095632","volume":"63","author":"L Panaite","year":"2022","unstructured":"Panaite, L. et al. Predictors of cytopenias after treatment with axicabtagene ciloleucel in patients with large B-cell lymphoma. Leukemia Lymphoma 63, 2918\u20132922 (2022).","journal-title":"Leukemia Lymphoma"},{"key":"992_CR21","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1002\/ajh.25951","volume":"95","author":"P Sesques","year":"2020","unstructured":"Sesques, P. et al. Commercial anti-CD19 CAR T cell therapy for patients with relapsed\/refractory aggressive B cell lymphoma in a European center. Am. J. Hematol. 95, 1324\u20131333 (2020).","journal-title":"Am. J. Hematol."},{"key":"992_CR22","doi-asserted-by":"crossref","first-page":"5976","DOI":"10.1111\/jcmm.17550","volume":"26","author":"L Iovino","year":"2022","unstructured":"Iovino, L. et al. Predictors of response to axicabtagene-ciloleucel CAR T cells in aggressive B cell lymphomas: a real-world study. J. Cell Mol. Med. 26, 5976\u20135983 (2022).","journal-title":"J. Cell Mol. Med."},{"key":"992_CR23","doi-asserted-by":"crossref","first-page":"5607","DOI":"10.1182\/bloodadvances.2020003001","volume":"4","author":"L Vercellino","year":"2020","unstructured":"Vercellino, L. et al. Predictive factors of early progression after CAR T-cell therapy in relapsed\/refractory diffuse large B-cell lymphoma. Blood Adv. 4, 5607\u20135615 (2020).","journal-title":"Blood Adv."},{"key":"992_CR24","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.bbmt.2020.09.028","volume":"27","author":"AS Kittai","year":"2021","unstructured":"Kittai, A. S. et al. Comorbidities predict inferior survival in patients receiving chimeric antigen receptor T cell therapy for diffuse large B cell lymphoma: a multicenter analysis. Transpl. Cell Ther. 27, 46\u201352 (2021).","journal-title":"Transpl. Cell Ther."},{"key":"992_CR25","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.hemonc.2021.09.001","volume":"16","author":"JV Forero-Forero","year":"2023","unstructured":"Forero-Forero, J. V. et al. Predictors and management of relapse to axicabtagene ciloleucel in patients with aggressive B-cell lymphoma. Hematol. Oncol. Stem Cell. Ther. 16, 133\u2013143 (2023).","journal-title":"Hematol. Oncol. Stem Cell. Ther."},{"key":"992_CR26","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.clml.2021.07.002","volume":"21","author":"S Ghafouri","year":"2021","unstructured":"Ghafouri, S. et al. Real-world experience of axicabtagene ciloleucel and tisagenlecleucel for relapsed or refractory aggressive B-cell lymphomas: a single-institution experience. Clin. Lymphoma Myeloma Leuk. 21, 861\u2013872 (2021).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"992_CR27","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1038\/s41591-022-01969-y","volume":"28","author":"E Bachy","year":"2022","unstructured":"Bachy, E. et al. A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma. Nat. Med. 28, 2145\u20132154 (2022).","journal-title":"Nat. Med."},{"key":"992_CR28","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1182\/blood.2019004162","volume":"135","author":"SS Neelapu","year":"2020","unstructured":"Neelapu, S. S. et al. Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma. Blood 135, 2106\u20132109 (2020).","journal-title":"Blood"},{"issue":"Suppl. 15","key":"992_CR29","doi-asserted-by":"crossref","first-page":"8039","DOI":"10.1200\/JCO.2020.38.15_suppl.8039","volume":"38","author":"L Fitzgerald","year":"2020","unstructured":"Fitzgerald, L. et al. Real-world outcomes of elderly patients with relapsed\/refractory (R\/R) diffuse large B-cell lymphoma (DLBCL) treated with chimeric antigen receptor T-cell (CAR-T) therapy [abstract]. J. Clin. Oncol. 38 (Suppl. 15), 8039 (2020).","journal-title":"J. Clin. Oncol."},{"key":"992_CR30","first-page":"349","volume":"140","author":"WA Bethge","year":"2022","unstructured":"Bethge, W. A. et al. GLA\/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany. Blood 140, 349\u2013358 (2022).","journal-title":"Blood"},{"issue":"Suppl. 1","key":"992_CR31","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1182\/blood-2019-127372","volume":"134","author":"ME Zettler","year":"2019","unstructured":"Zettler, M. E. et al. Real-world analysis of adverse events associated with CAR T-cell therapy among adults age \u226565 years [abstract]. Blood 134 (Suppl. 1), 1951 (2019).","journal-title":"Blood"},{"issue":"Suppl. 1","key":"992_CR32","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1182\/blood-2019-129593","volume":"134","author":"A Gajra","year":"2019","unstructured":"Gajra, A. et al. Neurological adverse events following CAR-T cell therapy: a real-world analysis of adult patients treated with axicabtagene ciloleucel or tisagenlecleucel [abstract]. Blood 134 (Suppl. 1), 1952 (2019).","journal-title":"Blood"},{"key":"992_CR33","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/ajh.26113","volume":"96","author":"SJ Nagle","year":"2021","unstructured":"Nagle, S. J. et al. Prolonged hematologic toxicity following treatment with chimeric antigen receptor T cells in patients with hematologic malignancies. Am. J. Hematol. 96, 455\u2013461 (2021).","journal-title":"Am. J. Hematol."},{"key":"992_CR34","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1182\/blood.2020010543","volume":"138","author":"K Rejeski","year":"2021","unstructured":"Rejeski, K. et al. CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed\/refractory large B-cell lymphoma. Blood 138, 2499\u20132513 (2021).","journal-title":"Blood"},{"key":"992_CR35","first-page":"1832","volume":"137","author":"JY Spiegel","year":"2021","unstructured":"Spiegel, J. Y. et al. Outcomes of patients with large B-cell lymphoma progressing after axicabtagene ciloleucel therapy. Blood 137, 1832\u20131835 (2021).","journal-title":"Blood"},{"issue":"Suppl. 1","key":"992_CR36","doi-asserted-by":"crossref","first-page":"3787","DOI":"10.1182\/blood-2023-186510","volume":"142","author":"VL Buecklein","year":"2023","unstructured":"Buecklein, V. L. et al. Impact of sex on clinical outcomes after CD19 CAR T-cell therapy for large B-cell lymphoma: response and survival are significantly superior in female compared to male patients [abstract]. Blood 142 (Suppl. 1), 3787 (2023).","journal-title":"Blood"},{"key":"992_CR37","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1093\/neuonc\/noaa183","volume":"23","author":"NG Holtzman","year":"2021","unstructured":"Holtzman, N. G. et al. Immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy for lymphoma: predictive biomarkers and clinical outcomes. Neuro Oncol. 23, 112\u2013121 (2021).","journal-title":"Neuro Oncol."},{"key":"992_CR38","doi-asserted-by":"crossref","first-page":"e984","DOI":"10.1097\/HS9.0000000000000984","volume":"7","author":"E Shumilov","year":"2023","unstructured":"Shumilov, E. et al. CAR-T cell therapy shows similar efficacy and toxicity in patients with DLBCL regardless of CNS involvement. HemaSphere 7, e984 (2023).","journal-title":"HemaSphere"},{"key":"992_CR39","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1182\/bloodadvances.2020001837","volume":"4","author":"CC Pinnix","year":"2020","unstructured":"Pinnix, C. C. et al. Bridging therapy prior to axicabtagene ciloleucel for relapsed\/refractory large B-cell lymphoma. Blood Adv. 4, 2871\u20132883 (2020).","journal-title":"Blood Adv."},{"key":"992_CR40","doi-asserted-by":"crossref","first-page":"4669","DOI":"10.1182\/bloodadvances.2020002118","volume":"4","author":"D Sermer","year":"2020","unstructured":"Sermer, D. et al. Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies. Blood Adv. 4, 4669\u20134678 (2020).","journal-title":"Blood Adv."},{"key":"992_CR41","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/bloodadvances.2020001900","volume":"4","author":"EA Dean","year":"2020","unstructured":"Dean, E. A. et al. High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv. 4, 3268\u20133276 (2020).","journal-title":"Blood Adv."},{"key":"992_CR42","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1182\/bloodadvances.2019000525","volume":"4","author":"R Awasthi","year":"2020","unstructured":"Awasthi, R. et al. Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed\/refractory DLBCL. Blood Adv. 4, 560\u2013572 (2020).","journal-title":"Blood Adv."},{"key":"992_CR43","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1182\/bloodadvances.2020002394","volume":"4","author":"FL Locke","year":"2020","unstructured":"Locke, F. L. et al. Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv. 4, 4898\u20134911 (2020).","journal-title":"Blood Adv."},{"key":"992_CR44","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","volume":"130","author":"KA Hay","year":"2017","unstructured":"Hay, K. A. et al. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. Blood 130, 2295\u20132306 (2017).","journal-title":"Blood"},{"key":"992_CR45","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1158\/2643-3230.BCD-23-0112","volume":"5","author":"S Filosto","year":"2024","unstructured":"Filosto, S. et al. Product attributes of CAR T-cell therapy differentially associate with efficacy and toxicity in second-line large B-cell lymphoma (ZUMA-7). Blood Cancer Discov. 5, 21\u201333 (2024).","journal-title":"Blood Cancer Discov."},{"issue":"Suppl. 1","key":"992_CR46","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1182\/blood-2019-129624","volume":"134","author":"MD Jain","year":"2019","unstructured":"Jain, M. D. et al. Characteristics and outcomes of patients receiving bridging therapy while awaiting manufacture of standard of care axicabtagene ciloleucel CD19 chimeric antigen receptor (CAR) T-cell therapy for relapsed\/refractory large B-cell lymphoma: results from the US Lymphoma CAR-T Consortium [abstract]. Blood 134 (Suppl. 1), 245 (2019).","journal-title":"Blood"},{"key":"992_CR47","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1182\/bloodadvances.2023011489","volume":"8","author":"MD Jain","year":"2024","unstructured":"Jain, M. D. et al. Bridging therapy with axicabtagene ciloleucel for large B-cell lymphoma: results from the US Lymphoma CAR-T Consortium [abstract]. Blood Adv. 8, 1042\u20131050 (2024).","journal-title":"Blood Adv."},{"key":"992_CR48","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ijrobp.2020.05.014","volume":"108","author":"CM Wright","year":"2020","unstructured":"Wright, C. M. et al. Bridging radiation therapy before commercial chimeric antigen receptor T-cell therapy for relapsed or refractory aggressive B-cell lymphoma. Int. J. Radiat. Oncol. Biol. Phys. 108, 178\u2013188 (2020).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"Suppl. 1","key":"992_CR49","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1182\/blood-2018-99-114152","volume":"132","author":"LJ Nastoupil","year":"2018","unstructured":"Nastoupil, L. J. et al. Axicabtagene ciloleucel (Axi-cel) CD19 chimeric antigen receptor (CAR) T-cell therapy for relapsed\/refractory large B-cell lymphoma: real world experience [abstract]. Blood 132 (Suppl. 1), 91 (2018).","journal-title":"Blood"},{"key":"992_CR50","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.3390\/cancers15061747","volume":"15","author":"C Ladbury","year":"2023","unstructured":"Ladbury, C. et al. Long-term follow-up of bridging therapies prior to CAR T-cell therapy for relapsed\/refractory large B cell lymphoma. Cancers 15, 1747 (2023).","journal-title":"Cancers"},{"issue":"Suppl. 1","key":"992_CR51","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1182\/blood-2019-129421","volume":"134","author":"J Paillassa","year":"2019","unstructured":"Paillassa, J. et al. Impact of bridging chemotherapy on clinical outcomes of CD19 CAR T therapy in relapse\/refractory diffuse large B-cell lymphoma in real world experience [abstract]. Blood 134 (Suppl. 1), 2886 (2019).","journal-title":"Blood"},{"key":"992_CR52","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1002\/ajh.27069","volume":"98","author":"SY Ong","year":"2023","unstructured":"Ong, S. Y. et al. Bendamustine lymphodepletion is a well-tolerated alternative to fludarabine and cyclophosphamide lymphodepletion for axicabtagene ciloleucel therapy for aggressive B-cell lymphoma. Am. J. Hematol. 98, 1751\u20131761 (2023).","journal-title":"Am. J. Hematol."},{"key":"992_CR53","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/j.annonc.2022.05.521","volume":"33","author":"G Ghilardi","year":"2022","unstructured":"Ghilardi, G. et al. Bendamustine is safe and effective for lymphodepletion before tisagenlecleucel in patients with refractory or relapsed large B-cell lymphomas. Ann. Oncol. 33, 916\u2013928 (2022).","journal-title":"Ann. Oncol."},{"key":"992_CR54","doi-asserted-by":"crossref","first-page":"8901","DOI":"10.2147\/CMAR.S321202","volume":"13","author":"A Schaefer","year":"2021","unstructured":"Schaefer, A. et al. Cytopenias after CD19 chimeric antigen receptor T-cells (CAR-T) therapy for diffuse large B-cell lymphomas or transformed follicular lymphoma: a single institution experience. Cancer Manag. Res. 13, 8901\u20138906 (2021).","journal-title":"Cancer Manag. Res."},{"key":"992_CR55","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3324\/haematol.2019.243246","volume":"106","author":"RJ Lin","year":"2021","unstructured":"Lin, R. J. et al. Impact and safety of chimeric antigen receptor T-cell therapy in older, vulnerable patients with relapsed\/refractory large B-cell lymphoma. Haematologica 106, 255\u2013258 (2021).","journal-title":"Haematologica"},{"key":"992_CR56","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1080\/10428194.2020.1864349","volume":"62","author":"A Mian","year":"2021","unstructured":"Mian, A. et al. Outcomes and factors impacting use of axicabtagene ciloleucel in patients with relapsed or refractory large B-cell lymphoma: results from an intention-to-treat analysis. Leuk. Lymphoma 62, 1344\u20131352 (2021).","journal-title":"Leuk. Lymphoma"},{"key":"992_CR57","doi-asserted-by":"crossref","first-page":"4789","DOI":"10.3390\/cancers13194789","volume":"13","author":"B Casadei","year":"2021","unstructured":"Casadei, B. et al. Real world evidence of CAR T-cell therapies for the treatment of relapsed\/refractory B-cell non-Hodgkin lymphoma: a monocentric experience. Cancers 13, 4789 (2021).","journal-title":"Cancers"},{"issue":"Suppl. 1","key":"992_CR58","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1182\/blood-2019-128302","volume":"134","author":"V Bachanova","year":"2019","unstructured":"Bachanova, V. et al. Impact of tisagenlecleucel chimeric antigen receptor (CAR)-T cell therapy product attributes on clinical outcomes in adults with relapsed or refractory diffuse large B-cell lymphoma (r\/r DLBCL) [abstract]. Blood 134 (Suppl. 1), 242 (2019).","journal-title":"Blood"},{"key":"992_CR59","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.clml.2022.05.004","volume":"22","author":"MT Jacobs","year":"2022","unstructured":"Jacobs, M. T. et al. Severity of cytokine release syndrome influences outcome after axicabtagene ciloleucel for large B cell lymphoma: results from the US Lymphoma CAR-T Consortium. Clin. Lymphoma Myeloma Leukemia 22, 753\u2013759 (2022).","journal-title":"Clin. Lymphoma Myeloma Leukemia"},{"key":"992_CR60","doi-asserted-by":"crossref","first-page":"4657","DOI":"10.1182\/bloodadvances.2022007057","volume":"6","author":"A Cuffel","year":"2022","unstructured":"Cuffel, A. et al. Real-world characteristics of T-cell apheresis and clinical response to tisagenlecleucel in B-cell lymphoma. Blood Adv. 6, 4657\u20134660 (2022).","journal-title":"Blood Adv."},{"key":"992_CR61","doi-asserted-by":"crossref","first-page":"1610914","DOI":"10.3389\/pore.2023.1610914","volume":"29","author":"M \u0160tach","year":"2023","unstructured":"\u0160tach, M. et al. Characterization of the input material quality for the production of tisagenlecleucel by multiparameter flow cytometry and its relation to the clinical outcome. Pathol. Oncol. Res. 29, 1610914 (2023).","journal-title":"Pathol. Oncol. Res."},{"key":"992_CR62","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1182\/bloodadvances.2024012563","volume":"8","author":"C Carniti","year":"2024","unstructured":"Carniti, C. et al. Monocytes in leukapheresis products affect the outcome of CD19-targeted CAR T-cell therapy in patients with lymphoma. Blood Adv. 8, 1968\u20131980 (2024).","journal-title":"Blood Adv."},{"key":"992_CR63","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1038\/s41591-022-01959-0","volume":"28","author":"NJ Haradhvala","year":"2022","unstructured":"Haradhvala, N. J. et al. Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma. Nat. Med. 28, 1848\u20131859 (2022).","journal-title":"Nat. Med."},{"key":"992_CR64","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1158\/1078-0432.CCR-22-0164","volume":"28","author":"C Monfrini","year":"2022","unstructured":"Monfrini, C. et al. Phenotypic composition of commercial anti-CD19 CAR T cells affects in vivo expansion and disease response in patients with large B-cell lymphoma. Clin. Cancer Res. 28, 3378\u20133386 (2022).","journal-title":"Clin. Cancer Res."},{"key":"992_CR65","doi-asserted-by":"crossref","first-page":"S192","DOI":"10.1016\/j.jtct.2023.12.249","volume":"30","author":"AJ Portuguese","year":"2024","unstructured":"Portuguese, A. J. et al. Real-world comparison of lisocabtagene maraleucel (Liso-Cel) and axicabtagene ciloleucel (Axi-Cel): efficacy & toxicity. Transplant. Cell. Ther. 30, S192 (2024).","journal-title":"Transplant. Cell. Ther."},{"key":"992_CR66","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1038\/s41591-020-1061-7","volume":"26","author":"Q Deng","year":"2020","unstructured":"Deng, Q. et al. Characteristics of anti-CD19 CAR-T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas. Nat. Med. 26, 1878\u20131887 (2020).","journal-title":"Nat. Med."},{"key":"992_CR67","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1056\/NEJMoa2301665","volume":"389","author":"JR Westin","year":"2023","unstructured":"Westin, J. R. et al. Survival with axicabtagene ciloleucel in large B-cell lymphoma. N. Engl. J. Med. 389, 148\u2013157 (2023).","journal-title":"N. Engl. J. Med."},{"key":"992_CR68","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","volume":"130","author":"M Crump","year":"2017","unstructured":"Crump, M. et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood 130, 1800\u20131808 (2017).","journal-title":"Blood"},{"key":"992_CR69","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/bmt.2015.213","volume":"51","author":"E Van Den Neste","year":"2016","unstructured":"Van Den Neste, E. et al. Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study. Bone Marrow Transpl. 51, 51\u201357 (2016).","journal-title":"Bone Marrow Transpl."},{"key":"992_CR70","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/s41409-019-0650-x","volume":"55","author":"E Gonz\u00e1lez-Barca","year":"2020","unstructured":"Gonz\u00e1lez-Barca, E. et al. Outcome in patients with diffuse large B-cell lymphoma who relapse after autologous stem cell transplantation and receive active therapy. A retrospective analysis of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transpl. 55, 393\u2013399 (2020).","journal-title":"Bone Marrow Transpl."},{"key":"992_CR71","doi-asserted-by":"crossref","first-page":"3490","DOI":"10.1200\/JCO.2013.53.9593","volume":"32","author":"M Crump","year":"2014","unstructured":"Crump, M. et al. Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12. J. Clin. Oncol. 32, 3490\u20133496 (2014).","journal-title":"J. Clin. Oncol."},{"key":"992_CR72","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","volume":"28","author":"C Gisselbrecht","year":"2010","unstructured":"Gisselbrecht, C. et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J. Clin. Oncol. 28, 4184\u20134190 (2010).","journal-title":"J. Clin. Oncol."},{"key":"992_CR73","first-page":"2307","volume":"141","author":"SS Neelapu","year":"2023","unstructured":"Neelapu, S. S. et al. Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma. Blood 141, 2307\u20132315 (2023).","journal-title":"Blood"},{"key":"992_CR74","doi-asserted-by":"crossref","first-page":"3581","DOI":"10.1200\/JCO.23.02786","volume":"42","author":"MD Jain","year":"2024","unstructured":"Jain, M. D. et al. Five-year follow-up of standard-of-care axicabtagene ciloleucel for large B-cell lymphoma: results from the US Lymphoma CAR T Consortium. J. Clin. Oncol. 42, 3581\u20133592 (2024).","journal-title":"J. Clin. Oncol."},{"key":"992_CR75","doi-asserted-by":"crossref","first-page":"581.e1","DOI":"10.1016\/j.jtct.2022.05.026","volume":"28","author":"CA Jacobson","year":"2022","unstructured":"Jacobson, C. A. et al. Real-world evidence of axicabtagene ciloleucel for the treatment of large B cell lymphoma in the United States. Transpl. Cell Ther. 28, 581.e1\u2013581.e8 (2022).","journal-title":"Transpl. Cell Ther."},{"key":"992_CR76","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S1470-2045(21)00375-2","volume":"22","author":"SJ Schuster","year":"2021","unstructured":"Schuster, S. J. et al. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 22, 1403\u20131415 (2021).","journal-title":"Lancet Oncol."},{"key":"992_CR77","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1182\/blood.2023020854","volume":"143","author":"JS Abramson","year":"2024","unstructured":"Abramson, J. S. et al. Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001. Blood 143, 404\u2013416 (2024).","journal-title":"Blood"},{"key":"992_CR78","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1182\/blood.2022018730","volume":"141","author":"JS Abramson","year":"2023","unstructured":"Abramson, J. S. et al. Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study. Blood 141, 1675\u20131684 (2023).","journal-title":"Blood"},{"issue":"Suppl. 1","key":"992_CR79","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1182\/blood-2023-180952","volume":"142","author":"AR Sehgal","year":"2023","unstructured":"Sehgal, A. R. et al. Lisocabtagene maraleucel as second-line therapy for R\/R large B-cell lymphoma in patients not intended for hematopoietic stem cell transplant: final analysis of the phase 2 PILOT study [abstract]. Blood 142 (Suppl. 1), 105 (2023).","journal-title":"Blood"},{"key":"992_CR80","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow, S. H. et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127, 2375\u20132390 (2016).","journal-title":"Blood"},{"issue":"Suppl. 1","key":"992_CR81","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1182\/blood-2023-174510","volume":"142","author":"JC Chavez","year":"2023","unstructured":"Chavez, J. C. et al. 3-year analysis of ZUMA-12: a phase 2 study of axicabtagene ciloleucel (Axi-Cel) as first-line therapy in patients with high-risk large B-cell lymphoma (LBCL) [abstract]. Blood 142 (Suppl. 1), 894 (2023).","journal-title":"Blood"},{"key":"992_CR82","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee, D. W. et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol. Blood Marrow Transplant. 25, 625\u2013638 (2019).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"992_CR83","first-page":"188","volume":"124","author":"DW Lee","year":"2014","unstructured":"Lee, D. W. et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood 124, 188\u2013195 (2014).","journal-title":"Blood"},{"key":"992_CR84","doi-asserted-by":"crossref","first-page":"e186","DOI":"10.1097\/HS9.0000000000000186","volume":"3","author":"L Y\u00e1\u00f1ez","year":"2019","unstructured":"Y\u00e1\u00f1ez, L., S\u00e1nchez-Escamilla, M. & Perales, M. A. CAR T cell toxicity: current management and future directions. HemaSphere 3, e186 (2019).","journal-title":"HemaSphere"},{"key":"992_CR85","doi-asserted-by":"publisher","unstructured":"Doan, A. & Pulsipher, M. A. Hypogammaglobulinemia due to CAR T-cell therapy. Pediatr. Blood Cancer, https:\/\/doi.org\/10.1002\/pbc.26914 (2018).","DOI":"10.1002\/pbc.26914"},{"key":"992_CR86","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","volume":"20","author":"FL Locke","year":"2019","unstructured":"Locke, F. L. et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet. Oncol. 20, 31\u201342 (2019).","journal-title":"Lancet. Oncol."},{"key":"992_CR87","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1093\/cid\/ciae291","volume":"79","author":"JA Hill","year":"2024","unstructured":"Hill, J. A. et al. SARS-CoV-2 vaccination in the first year after hematopoietic cell transplant or chimeric antigen receptor T-cell therapy: a prospective, multicenter, observational study. Clin. Infect. Dis. 79, 542\u2013554 (2024).","journal-title":"Clin. Infect. Dis."},{"key":"992_CR88","doi-asserted-by":"publisher","unstructured":"Sharma, N., Reagan, P. M. & Liesveld, J. L. Cytopenia after CAR-T cell therapy \u2013 a brief review of a complex problem. Cancers, https:\/\/doi.org\/10.3390\/cancers14061501 (2022).","DOI":"10.3390\/cancers14061501"},{"key":"992_CR89","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1182\/blood.2023020578","volume":"142","author":"K Rejeski","year":"2023","unstructured":"Rejeski, K. et al. Immune effector cell-associated hematotoxicity: EHA\/EBMT consensus grading and best practice recommendations. Blood 142, 865\u2013877 (2023).","journal-title":"Blood"},{"key":"992_CR90","doi-asserted-by":"crossref","first-page":"438.e1","DOI":"10.1016\/j.jtct.2023.03.006","volume":"29","author":"MR Hines","year":"2023","unstructured":"Hines, M. R. et al. Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome. Transpl. Cell Ther. 29, 438.e1\u2013438.e16 (2023).","journal-title":"Transpl. Cell Ther."},{"key":"992_CR91","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.bbmt.2020.02.012","volume":"26","author":"V Gutgarts","year":"2020","unstructured":"Gutgarts, V. et al. Acute kidney injury after CAR-T cell therapy: low incidence and rapid recovery. Biol. Blood Marrow Transpl. 26, 1071\u20131076 (2020).","journal-title":"Biol. Blood Marrow Transpl."},{"key":"992_CR92","first-page":"18","volume":"9","author":"DH Lee","year":"2023","unstructured":"Lee, D. H. et al. Cardiac and inflammatory biomarker differences in adverse cardiac events after chimeric antigen receptor T-cell therapy: an exploratory study. Cardiooncology 9, 18 (2023).","journal-title":"Cardiooncology"},{"key":"992_CR93","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJMp2400209","volume":"390","author":"N Verdun","year":"2024","unstructured":"Verdun, N. & Marks, P. Secondary cancers after chimeric antigen receptor T-cell therapy. N. Engl. J. Med. 390, 584\u2013586 (2024).","journal-title":"N. Engl. J. Med."},{"key":"992_CR94","doi-asserted-by":"crossref","first-page":"6589","DOI":"10.1182\/bloodadvances.2023010624","volume":"7","author":"J Lemoine","year":"2023","unstructured":"Lemoine, J. et al. Nonrelapse mortality after CAR T-cell therapy for large B-cell lymphoma: a LYSA study from the DESCAR-T registry. Blood Adv. 7, 6589\u20136598 (2023).","journal-title":"Blood Adv."},{"key":"992_CR95","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1038\/s41591-024-03084-6","volume":"30","author":"DM Cordas dos Santos","year":"2024","unstructured":"Cordas dos Santos, D. M. et al. A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy. Nat. Med. 30, 2667\u20132678 (2024).","journal-title":"Nat. Med."},{"key":"992_CR96","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/s41591-024-02826-w","volume":"30","author":"G Ghilardi","year":"2024","unstructured":"Ghilardi, G. et al. T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy. Nat. Med. 30, 984\u2013989 (2024).","journal-title":"Nat. Med."},{"key":"992_CR97","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1182\/blood.2024024166","volume":"143","author":"M Elsallab","year":"2024","unstructured":"Elsallab, M. et al. Second primary malignancies after commercial CAR T-cell therapy: analysis of the FDA adverse events reporting system. Blood 143, 2099\u20132105 (2024).","journal-title":"Blood"},{"key":"992_CR98","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1056\/NEJMoa2401361","volume":"390","author":"MP Hamilton","year":"2024","unstructured":"Hamilton, M. P. et al. Risk of second tumors and T-cell lymphoma after CAR T-cell therapy. N. Engl. J. Med. 390, 2047\u20132060 (2024).","journal-title":"N. Engl. J. Med."},{"key":"992_CR99","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1182\/blood.2021010858","volume":"138","author":"KP Micklethwaite","year":"2021","unstructured":"Micklethwaite, K. P. et al. Investigation of product-derived lymphoma following infusion of piggyBac-modified CD19 chimeric antigen receptor T cells. Blood 138, 1391\u20131405 (2021).","journal-title":"Blood"},{"issue":"Suppl. 1","key":"992_CR100","doi-asserted-by":"crossref","first-page":"6939","DOI":"10.1182\/blood-2023-178806","volume":"142","author":"SJ Harrison","year":"2023","unstructured":"Harrison, S. J. et al. CAR+ T-cell lymphoma post ciltacabtagene autoleucel therapy for relapsed refractory multiple myeloma [abetract]. Blood 142 (Suppl. 1), 6939 (2023).","journal-title":"Blood"},{"key":"992_CR101","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1182\/blood.2020010497","volume":"138","author":"D Chihara","year":"2021","unstructured":"Chihara, D., Dores, G. M., Flowers, C. R. & Morton, L. M. The bidirectional increased risk of B-cell lymphoma and T-cell lymphoma. Blood 138, 785\u2013789 (2021).","journal-title":"Blood"},{"key":"992_CR102","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1182\/bloodadvances.2020003503","volume":"5","author":"DL Patrick","year":"2021","unstructured":"Patrick, D. L. et al. Effect of lisocabtagene maraleucel on HRQoL and symptom severity in relapsed\/refractory large B-cell lymphoma. Blood Adv. 5, 2245\u20132255 (2021).","journal-title":"Blood Adv."},{"key":"992_CR103","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1182\/bloodadvances.2019001026","volume":"4","author":"RT Maziarz","year":"2020","unstructured":"Maziarz, R. T. et al. Patient-reported long-term quality of life after tisagenlecleucel in relapsed\/refractory diffuse large B-cell lymphoma. Blood Adv. 4, 629\u2013637 (2020).","journal-title":"Blood Adv."},{"issue":"Suppl. 1","key":"992_CR104","first-page":"5190","volume":"140","author":"HSL Jim","year":"2022","unstructured":"Jim, H. S. L. et al. Real-world patient-reported outcomes among recipients of axicabtagene ciloleucel for relapsed\/refractory large B cell lymphoma [abstract]. Blood 140 (Suppl. 1), 5190\u20135191 (2022).","journal-title":"Blood"},{"key":"992_CR105","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1182\/blood.2022015478","volume":"140","author":"M Elsawy","year":"2022","unstructured":"Elsawy, M. et al. Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma. Blood 140, 2248\u20132260 (2022).","journal-title":"Blood"},{"key":"992_CR106","doi-asserted-by":"crossref","first-page":"5969","DOI":"10.1182\/bloodadvances.2022008106","volume":"6","author":"JS Abramson","year":"2022","unstructured":"Abramson, J. S. et al. Health-related quality of life with lisocabtagene maraleucel vs standard of care in relapsed or refractory LBCL. Blood Adv. 6, 5969\u20135979 (2022).","journal-title":"Blood Adv."},{"key":"992_CR107","doi-asserted-by":"crossref","first-page":"3521","DOI":"10.2169\/internalmedicine.0990-18","volume":"57","author":"A Tanimura","year":"2018","unstructured":"Tanimura, A. et al. The prognostic impact of dose-attenuated R-CHOP therapy for elderly patients with diffuse large B-cell lymphoma. Intern. Med. 57, 3521\u20133528 (2018).","journal-title":"Intern. Med."},{"issue":"Suppl. 1","key":"992_CR108","doi-asserted-by":"crossref","first-page":"4581","DOI":"10.1182\/blood-2021-153702","volume":"138","author":"VA Guerra","year":"2021","unstructured":"Guerra, V. A., Ocampo, M. & Cusnir, M. Outcomes of R-Mini-CHOP therapy for elderly patients with diffused large B cell lymphoma (DLBCL) and high-grade follicular lymphoma (FL) [abstract]. Blood 138 (Suppl. 1), 4581 (2021).","journal-title":"Blood"},{"key":"992_CR109","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13045-024-01579-w","volume":"17","author":"P Sesques","year":"2024","unstructured":"Sesques, P. et al. Novel prognostic scoring systems for severe CRS and ICANS after anti-CD19 CAR T cells in large B-cell lymphoma. J. Hematol. Oncol. 17, 61 (2024).","journal-title":"J. Hematol. Oncol."},{"key":"992_CR110","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-017-0023-x","volume":"7","author":"E Mejstr\u00edkov\u00e1","year":"2017","unstructured":"Mejstr\u00edkov\u00e1, E. et al. CD19-negative relapse of pediatric B-cell precursor acute lymphoblastic leukemia following blinatumomab treatment. Blood Cancer J. 7, 659 (2017).","journal-title":"Blood Cancer J."},{"key":"992_CR111","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1200\/JCO.21.01405","volume":"40","author":"RM Myers","year":"2022","unstructured":"Myers, R. M. et al. Blinatumomab nonresponse and high-disease burden are associated with inferior outcomes after CD19-CAR for B-ALL. J. Clin. Oncol. 40, 932\u2013944 (2022).","journal-title":"J. Clin. Oncol."},{"key":"992_CR112","doi-asserted-by":"crossref","first-page":"5371","DOI":"10.1182\/bloodadvances.2024013726","volume":"8","author":"V Camus","year":"2024","unstructured":"Camus, V. et al. Outcome of patients with large B-cell lymphoma treated with tafasitamab plus lenalidomide either before or after CAR T-cell therapy. Blood Adv. 8, 5371\u20135381 (2024).","journal-title":"Blood Adv."},{"key":"992_CR113","first-page":"100260","volume":"16","author":"N Tabbara","year":"2021","unstructured":"Tabbara, N., Gaut, D., Oliai, C., Lewis, T. & de Vos, S. Anti-CD19 CAR T-cell therapy remission despite prior anti-CD19 antibody tafasitamab in relapsed\/refractory DLBCL. Leuk. Res. Rep. 16, 100260 (2021).","journal-title":"Leuk. Res. Rep."},{"key":"992_CR114","doi-asserted-by":"crossref","first-page":"3850","DOI":"10.1182\/bloodadvances.2020002587","volume":"4","author":"B Thapa","year":"2020","unstructured":"Thapa, B. et al. CD19 antibody-drug conjugate therapy in DLBCL does not preclude subsequent responses to CD19-directed CAR T-cell therapy. Blood Adv. 4, 3850\u20133852 (2020).","journal-title":"Blood Adv."},{"issue":"Suppl. 1","key":"992_CR115","doi-asserted-by":"crossref","first-page":"12089","DOI":"10.1182\/blood-2022-158595","volume":"140","author":"M Veeraputhiran","year":"2022","unstructured":"Veeraputhiran, M. et al. Tafasitamab (TAFA) plus lenalidomide (LEN) prior to chimeric antigen receptor T-cell (CAR-T) therapy in relapsed\/refractory (R\/R) diffuse large B-cell lymphoma (DLBCL): case series of 8 patients [abstract]. Blood 140 (Suppl. 1), 12089\u201312091 (2022).","journal-title":"Blood"},{"key":"992_CR116","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1182\/blood.2023021620","volume":"143","author":"FL Locke","year":"2024","unstructured":"Locke, F. L. et al. Axicabtagene ciloleucel vs standard of care in second-line large B-cell lymphoma: outcomes by metabolic tumor volume. Blood 143, 2464\u20132473 (2024).","journal-title":"Blood"},{"key":"992_CR117","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s40164-021-00248-9","volume":"10","author":"E Rabinovich","year":"2021","unstructured":"Rabinovich, E. et al. Elevated LDH greater than 400 U\/L portends poorer overall survival in diffuse large B-cell lymphoma patients treated with CD19 CAR-T cell therapy in a real world multi-ethnic cohort. Exp. Hematol. Oncol. 10, 55 (2021).","journal-title":"Exp. Hematol. Oncol."},{"key":"992_CR118","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1182\/bloodadvances.2024012992","volume":"9","author":"A Looka","year":"2024","unstructured":"Looka, A. et al. A real-world comparison of commercial use axicabtagene ciloleucel and lisocabtagene maraleucel in large B-cell lymphoma. Blood Adv. 9, 455\u2013462 (2024).","journal-title":"Blood Adv."},{"key":"992_CR119","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1001\/jamaoncol.2023.4504","volume":"10","author":"M Ventin","year":"2024","unstructured":"Ventin, M. et al. Implications of high tumor burden on chimeric antigen receptor T-cell immunotherapy: a review. JAMA Oncol. 10, 115\u2013121 (2024).","journal-title":"JAMA Oncol."},{"key":"992_CR120","first-page":"3153","volume":"141","author":"ME Selli","year":"2023","unstructured":"Selli, M. E. et al. Costimulatory domains direct distinct fates of CAR-driven T-cell dysfunction. Blood 141, 3153\u20133165 (2023).","journal-title":"Blood"},{"key":"992_CR121","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1182\/blood.2020007445","volume":"137","author":"MD Jain","year":"2021","unstructured":"Jain, M. D. et al. Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma. Blood 137, 2621\u20132633 (2021).","journal-title":"Blood"},{"key":"992_CR122","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","volume":"36","author":"R Alaggio","year":"2022","unstructured":"Alaggio, R. et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia 36, 1720\u20131748 (2022).","journal-title":"Leukemia"},{"key":"992_CR123","doi-asserted-by":"crossref","first-page":"349.e1","DOI":"10.1016\/j.jtct.2023.02.021","volume":"29","author":"N Dong","year":"2023","unstructured":"Dong, N. et al. Outcomes of CD19-directed chimeric antigen receptor T cell therapy for transformed nonfollicular lymphoma. Transpl. Cell Ther. 29, 349.e1\u2013349.e8 (2023).","journal-title":"Transpl. Cell Ther."},{"key":"992_CR124","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/s41591-023-02754-1","volume":"30","author":"FL Locke","year":"2024","unstructured":"Locke, F. L. et al. Impact of tumor microenvironment on efficacy of anti-CD19 CAR T cell therapy or chemotherapy and transplant in large B cell lymphoma. Nat. Med. 30, 507\u2013518 (2024).","journal-title":"Nat. Med."},{"key":"992_CR125","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1038\/s41591-022-01916-x","volume":"28","author":"N Scholler","year":"2022","unstructured":"Scholler, N. et al. Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma. Nat. Med. 28, 1872\u20131882 (2022).","journal-title":"Nat. Med."},{"key":"992_CR126","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1158\/1535-7163.MCT-21-0506","volume":"22","author":"NE Olson","year":"2023","unstructured":"Olson, N. E. et al. Exploration of tumor biopsy gene signatures to understand the role of the tumor microenvironment in outcomes to lisocabtagene maraleucel. Mol. Cancer Ther. 22, 406\u2013418 (2023).","journal-title":"Mol. Cancer Ther."},{"key":"992_CR127","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1200\/JCO.21.02143","volume":"40","author":"R Shouval","year":"2022","unstructured":"Shouval, R. et al. Impact of TP53 genomic alterations in large B-cell lymphoma treated with CD19-chimeric antigen receptor T-cell therapy. J. Clin. Oncol. 40, 369\u2013381 (2022).","journal-title":"J. Clin. Oncol."},{"key":"992_CR128","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1182\/blood.2021015008","volume":"140","author":"MD Jain","year":"2022","unstructured":"Jain, M. D. et al. Whole-genome sequencing reveals complex genomic features underlying anti-CD19 CAR T-cell treatment failures in lymphoma. Blood 140, 491\u2013503 (2022).","journal-title":"Blood"},{"key":"992_CR129","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1182\/blood.2022015601","volume":"140","author":"HJ Cherng","year":"2022","unstructured":"Cherng, H. J. et al. Risk assessment with low-pass whole-genome sequencing of cell-free DNA before CD19 CAR T-cell therapy for large B-cell lymphoma. Blood 140, 504\u2013515 (2022).","journal-title":"Blood"},{"key":"992_CR130","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/bjh.17738","volume":"195","author":"F Lutfi","year":"2021","unstructured":"Lutfi, F. et al. The impact of bridging therapy prior to CD19-directed chimeric antigen receptor T-cell therapy in patients with large B-cell lymphoma. Br. J. Haematol. 195, 405\u2013412 (2021).","journal-title":"Br. J. Haematol."},{"key":"992_CR131","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/s41571-022-00607-3","volume":"19","author":"L Amini","year":"2022","unstructured":"Amini, L. et al. Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion. Nat. Rev. Clin. Oncol. 19, 342\u2013355 (2022).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"992_CR132","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1182\/bloodadvances.2021004575","volume":"5","author":"U Greenbaum","year":"2021","unstructured":"Greenbaum, U. et al. CRP and ferritin in addition to the EASIX score predict CAR-T-related toxicity. Blood Adv. 5, 2799\u20132806 (2021).","journal-title":"Blood Adv."},{"key":"992_CR133","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","volume":"7","author":"J Gust","year":"2017","unstructured":"Gust, J. et al. Endothelial activation and blood\u2013brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discov. 7, 1404\u20131419 (2017).","journal-title":"Cancer Discov."},{"key":"992_CR134","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1182\/bloodadvances.2021006418","volume":"6","author":"VA Fabrizio","year":"2022","unstructured":"Fabrizio, V. A. et al. Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy. Blood Adv. 6, 1961\u20131968 (2022).","journal-title":"Blood Adv."},{"key":"992_CR135","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1182\/blood-2018-11-887067","volume":"133","author":"AV Hirayama","year":"2019","unstructured":"Hirayama, A. V. et al. The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR-T cells. Blood 133, 1876\u20131887 (2019).","journal-title":"Blood"},{"key":"992_CR136","doi-asserted-by":"crossref","first-page":"355ra116","DOI":"10.1126\/scitranslmed.aaf8621","volume":"8","author":"CJ Turtle","year":"2016","unstructured":"Turtle, C. J. et al. Immunotherapy of non-Hodgkin\u2019s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells. Sci. Transl. Med. 8, 355ra116 (2016).","journal-title":"Sci. Transl. Med."},{"key":"992_CR137","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1200\/JCO.20.01342","volume":"38","author":"CA Ramos","year":"2020","unstructured":"Ramos, C. A. et al. Anti-CD30 CAR-T cell therapy in relapsed and refractory hodgkin lymphoma. J. Clin. Oncol. 38, 3794\u20133804 (2020).","journal-title":"J. Clin. Oncol."},{"key":"992_CR138","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1182\/bloodadvances.2023011492","volume":"8","author":"G Ghilardi","year":"2024","unstructured":"Ghilardi, G. et al. Bendamustine lymphodepletion before axicabtagene ciloleucel is safe and associates with reduced inflammatory cytokines. Blood Adv. 8, 653\u2013666 (2024).","journal-title":"Blood Adv."},{"key":"992_CR139","doi-asserted-by":"crossref","first-page":"e008975","DOI":"10.1136\/jitc-2024-008975","volume":"12","author":"S Bharadwaj","year":"2024","unstructured":"& Bharadwaj, S. et al. Bendamustine is a safe and effective lymphodepletion agent for axicabtagene ciloleucel in patients with refractory or relapsed large B-cell lymphoma. J. Immunother. Cancer 12, e008975 (2024).","journal-title":"J. Immunother. Cancer"},{"key":"992_CR140","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13045-024-01542-9","volume":"17","author":"G Ghilardi","year":"2024","unstructured":"Ghilardi, G. et al. Efficacy and safety of bendamustine for lymphodepletion before lisocabtagene maraleucel. J. Hematol. Oncol. 17, 19 (2024).","journal-title":"J. Hematol. Oncol."},{"key":"992_CR141","doi-asserted-by":"crossref","first-page":"77.e1","DOI":"10.1016\/j.jtct.2023.10.017","volume":"30","author":"CA Jacobson","year":"2024","unstructured":"Jacobson, C. A. et al. Real-world outcomes with chimeric antigen receptor T cell therapies in large B cell lymphoma: a systematic review and meta-analysis. Transplant. Cell. Ther. 30, 77.e1\u201377.e15 (2024).","journal-title":"Transplant. Cell. Ther."},{"key":"992_CR142","doi-asserted-by":"crossref","first-page":"eabe2606","DOI":"10.1126\/scisignal.abe2606","volume":"14","author":"AI Salter","year":"2021","unstructured":"Salter, A. I. et al. Comparative analysis of TCR and CAR signaling informs CAR designs with superior antigen sensitivity and in vivo function. Sci. Signal. 14, eabe2606 (2021).","journal-title":"Sci. Signal."},{"key":"992_CR143","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/nri.2017.146","volume":"18","author":"AN Henning","year":"2018","unstructured":"Henning, A. N., Roychoudhuri, R. & Restifo, N. P. Epigenetic control of CD8+ T cell differentiation. Nat. Rev. Immunol. 18, 340\u2013356 (2018).","journal-title":"Nat. Rev. Immunol."},{"key":"992_CR144","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1158\/2159-8290.CD-18-1314","volume":"9","author":"RK Das","year":"2019","unstructured":"Das, R. K., Vernau, L., Grupp, S. A. & Barrett, D. M. Na\u00efve T-cell deficits at diagnosis and after chemotherapy impair cell therapy potential in pediatric cancers. Cancer Discov. 9, 492\u2013499 (2019).","journal-title":"Cancer Discov."},{"key":"992_CR145","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/leu.2015.247","volume":"30","author":"D Sommermeyer","year":"2016","unstructured":"Sommermeyer, D. et al. Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo. Leukemia 30, 492\u2013500 (2016).","journal-title":"Leukemia"},{"key":"992_CR146","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.omtm.2021.06.014","volume":"22","author":"X Wang","year":"2021","unstructured":"Wang, X. et al. Depletion of high-content CD14+ cells from apheresis products is critical for successful transduction and expansion of CAR T cells during large-scale cGMP manufacturing. Mol. Ther. Methods Clin. Dev. 22, 377\u2013387 (2021).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"992_CR147","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-52503-2","volume":"15","author":"S Fiorenza","year":"2024","unstructured":"Fiorenza, S. et al. Histone marks identify novel transcription factors that parse CAR-T subset-of-origin, clinical potential and expansion. Nat. Commun. 15, 8309 (2024).","journal-title":"Nat. Commun."},{"key":"992_CR148","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-13880-1","volume":"11","author":"A Sheih","year":"2020","unstructured":"Sheih, A. et al. Clonal kinetics and single-cell transcriptional profiling of CAR-T cells in patients undergoing CD19 CAR-T immunotherapy. Nat. Commun. 11, 219 (2020).","journal-title":"Nat. Commun."},{"key":"992_CR149","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1002\/cam4.3686","volume":"10","author":"Z Ying","year":"2021","unstructured":"Ying, Z. et al. Relmacabtagene autoleucel (relma-cel) CD19 CAR-T therapy for adults with heavily pretreated relapsed\/refractory large B-cell lymphoma in China. Cancer Med. 10, 999\u20131011 (2021).","journal-title":"Cancer Med."},{"key":"992_CR150","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/s41591-019-0421-7","volume":"25","author":"Z Ying","year":"2019","unstructured":"Ying, Z. et al. A safe and potent anti-CD19 CAR T cell therapy. Nat. Med. 25, 947\u2013953 (2019).","journal-title":"Nat. Med."},{"key":"992_CR151","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/hon.2807","volume":"39","author":"R Cui","year":"2021","unstructured":"Cui, R. et al. Humanized anti-CD19 chimeric antigen receptor-T cell therapy is safe and effective in lymphoma and leukemia patients with chronic and resolved hepatitis B virus infection. Hematol. Oncol. 39, 75\u201386 (2021).","journal-title":"Hematol. Oncol."},{"key":"992_CR152","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1182\/blood-2015-12-686725","volume":"127","author":"X Wang","year":"2016","unstructured":"Wang, X. et al. Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL. Blood 127, 2980\u20132990 (2016).","journal-title":"Blood"},{"key":"992_CR153","doi-asserted-by":"crossref","first-page":"e002328","DOI":"10.1136\/jitc-2020-002328","volume":"9","author":"Z Bai","year":"2021","unstructured":"Bai, Z. et al. Single-cell multiomics dissection of basal and antigen-specific activation states of CD19-targeted CAR-T cells. J. Immunother. Cancer 9, e002328 (2021).","journal-title":"J. Immunother. Cancer"},{"issue":"Suppl. 1","key":"992_CR154","doi-asserted-by":"crossref","first-page":"4872","DOI":"10.1182\/blood-2023-181663","volume":"142","author":"R Awasthi","year":"2023","unstructured":"Awasthi, R. et al. Long term durable responses in relapsed\/refractory (r\/r) ALL, DLBCL, and FL patients treated with tisagenlecleucel and its association with persistence of CAR T-cells [abstract]. Blood 142 (Suppl. 1), 4872 (2023).","journal-title":"Blood"},{"key":"992_CR155","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1182\/bloodadvances.2024012637","volume":"8","author":"MP Hamilton","year":"2024","unstructured":"Hamilton, M. P. et al. CAR19 monitoring by peripheral blood immunophenotyping reveals histology-specific expansion and toxicity. Blood Adv. 8, 3314\u20133326 (2024).","journal-title":"Blood Adv."},{"key":"992_CR156","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1038\/s41591-022-01960-7","volume":"28","author":"Z Good","year":"2022","unstructured":"Good, Z. et al. Post-infusion CAR TReg cells identify patients resistant to CD19-CAR therapy. Nat. Med. 28, 1860\u20131871 (2022).","journal-title":"Nat. Med."},{"key":"992_CR157","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1182\/bloodadvances.2023012073","volume":"8","author":"N Denlinger","year":"2024","unstructured":"Denlinger, N. et al. Post-infusion PD-1+ CD8+ CAR-T cells identify patients responsive to CD19 CAR-T therapy in non-Hodgkin lymphoma. Blood Adv. 8, 3140\u20133153 (2024).","journal-title":"Blood Adv."},{"key":"992_CR158","doi-asserted-by":"crossref","first-page":"6131","DOI":"10.1007\/s00432-023-04587-4","volume":"149","author":"TW Georgi","year":"2023","unstructured":"Georgi, T. W. et al. Prognostic value of baseline and early response FDG-PET\/CT in patients with refractory and relapsed aggressive B-cell lymphoma undergoing CAR-T cell therapy. J. Cancer Res. Clin. Oncol. 149, 6131\u20136138 (2023).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"992_CR159","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3324\/haematol.2021.280550","volume":"108","author":"J Galtier","year":"2023","unstructured":"Galtier, J. et al. Positron emission tomography-imaging assessment for guiding strategy in patients with relapsed\/refractory large B-cell lymphoma receiving CAR T cells. Haematologica 108, 171\u2013180 (2023).","journal-title":"Haematologica"},{"key":"992_CR160","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1182\/bloodadvances.2021005807","volume":"6","author":"A Kuhnl","year":"2022","unstructured":"Kuhnl, A. et al. Early FDG-PET response predicts CAR-T failure in large B-cell lymphoma. Blood Adv. 6, 321\u2013326 (2022).","journal-title":"Blood Adv."},{"issue":"Suppl. 15","key":"992_CR161","doi-asserted-by":"crossref","first-page":"7560","DOI":"10.1200\/JCO.2019.37.15_suppl.7560","volume":"37","author":"R Sirous","year":"2019","unstructured":"Sirous, R. et al. Early imaging biomarker assessment to predict long-term responses for large B-cell lymphoma (LBCL) after CAR-T therapy. J. Clin. Oncol. 37 (Suppl. 15), 7560 (2019).","journal-title":"J. Clin. Oncol."},{"key":"992_CR162","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1182\/bloodadvances.2021006715","volume":"6","author":"A Al Zaki","year":"2022","unstructured":"Al Zaki, A. et al. Day 30 SUVmax predicts progression in patients with lymphoma achieving PR\/SD after CAR T-cell therapy. Blood Adv. 6, 2867\u20132871 (2022).","journal-title":"Blood Adv."},{"key":"992_CR163","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1200\/JCO.2018.78.5246","volume":"36","author":"DM Kurtz","year":"2018","unstructured":"Kurtz, D. M. et al. Circulating tumor DNA measurements as early outcome predictors in diffuse large B-cell lymphoma. J. Clin. Oncol. 36, 2845\u20132853 (2018).","journal-title":"J. Clin. Oncol."},{"key":"992_CR164","doi-asserted-by":"crossref","first-page":"3034","DOI":"10.1200\/JCO.21.00377","volume":"39","author":"MJ Frank","year":"2021","unstructured":"Frank, M. J. et al. Monitoring of circulating tumor DNA improves early relapse detection after axicabtagene ciloleucel infusion in large B-cell lymphoma: results of a prospective multi-institutional trial. J. Clin. Oncol. 39, 3034\u20133043 (2021).","journal-title":"J. Clin. Oncol."},{"key":"992_CR165","doi-asserted-by":"crossref","first-page":"4765","DOI":"10.1182\/bloodadvances.2022008937","volume":"7","author":"ST Bhaskar","year":"2023","unstructured":"Bhaskar, S. T. et al. Chimeric antigen receptor T-cell therapy yields similar outcomes in patients with and without cytokine release syndrome. Blood Adv. 7, 4765\u20134772 (2023).","journal-title":"Blood Adv."},{"key":"992_CR166","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","volume":"16","author":"MS Topp","year":"2015","unstructured":"Topp, M. S. et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre single-arm phase 2 study. Lancet Oncol. 16, 57\u201366 (2015).","journal-title":"Lancet Oncol."}],"container-title":["Nature Reviews Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41571-025-00992-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-025-00992-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-025-00992-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T20:43:57Z","timestamp":1742935437000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41571-025-00992-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,18]]},"references-count":166,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["992"],"URL":"https:\/\/doi.org\/10.1038\/s41571-025-00992-5","relation":{},"ISSN":["1759-4774","1759-4782"],"issn-type":[{"value":"1759-4774","type":"print"},{"value":"1759-4782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,18]]},"assertion":[{"value":"27 January 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.F. holds patents and receives licensing fees for patents for improving the efficacy of CAR T cell therapy. S.F. is the chair of the clinical advisory board for Arovella Therapeutics and consults ad hoc for Prescient Therapeutics. C.J.T. receives research funding from 10X Genomics, Genscript, Juno Therapeutics\/BMS and Nektar Therapeutics; is a member of the Scientific Advisory Boards of Advesya, ArsenalBio, Cargo Therapeutics, Caribou Biosciences, Celgene\/BMS Cell Therapy, Differentia Bio, eGlint, Myeloid Therapeutics and T-CURX; is a member of the Data and Safety Monitoring Board of Kyverna; has acted as ad hoc adviser and\/or consultant (in the past 12 months) to Abbvie, Century Therapeutics, Prescient Therapeutics, Novartis, and Merck Sharp and Dohme; holds stock options in ArsenalBio, Cargo Therapeutics, Caribou Biosciences, eGlint, Eureka Therapeutics and Myeloid Therapeutics; has acted as a speaker for Novartis and Pfizer; and is listed as an inventor on patents related to lisocel and other CAR T cells. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}